Mye bra fra rapporten. God vekst og sterke signaler om fortsatt salgsvekst, bortsett fra Kina hvor en vil se avtagende salg ut året grunnet ny prosess rundt tendering. Regner med den negative effekten vil være midlertidig.
In the second quarter of 2024, the company recorded sales of NOK 38.3 million at 12% growth vs. 2Q23, a 13% organic growth. Sales revenue 1H24 were NOK 76.8 million, up 17% (16% organic growth) versus 1H23.
Sales in 2Q24 were primarily driven by very strong fCAL® turbo sales and good Cystatin C
sales growth in Europe. Within the ‘other’ category, both GCAL ® as well as cCRP contributed to a 25% growth vs 2Q23 and 18% growth in 1H24 vs 1H23.
Sales of Cystatin C were NOK 13.3 million during 2Q24 and at NOK 28.2 million in 1H24 vs 1H23, with 8% and 9% growth, respectively. Strong momentum in Europe was offset by slowing order demand from China and flat sales in the US in 2Q24. After a first wave of Cystatin C testing adoption in the US, new accounts are in the process of being acquired and should fuel continued future growth after the publication of the new global KDIGO guidelines. Full commercial impact of the new guidelines had already been projected to be effective after 3-5 years after guideline publication.
In China the implementation of a new regional tendering process has led to cautious ordering behaviour by the local partners in the concerned regions, a situation which is expected to continue in 2H24.
Sales of fCAL® turbo, which supports fast diagnosis of inflammatory bowel disease, reached a new record level of NOK 15 million in 2Q24 compared to NOK 12 million in 2Q23, a 26% increase in sales. For 1H24, fCAL® turbo sales were NOK 28.7 million vs. NOK 21.5 million in 1H23. Successful expansion and partnering efforts by Bühlmann Laboratories, our exclusive global commercialisation partner, are leading to continued record sales performance. An additional aspect is continuously improved workflow and automation elements of the fCAL® turbo assay
with productivity gains appealing to the market.
The company’s Swedish distribution subsidiary, Gentian Diagnostics AB (GAB), saw flat sales performance in 1H24 vs. 1H23, with slightly delayed orders by large accounts in 2Q as well
as some backorder situations for selected products, which contributed to a 20% sales decrease in 2Q24 vs 2Q23. Overall sales were NOK 9.3 million in 1H24
Pipeline
Gentian continues overseeing two proof-ofconcept projects. The project, conducted in close collaboration with a leading in vitro diagnostics (IVD) company, has advanced significantly, earning high satisfaction from the company’s partner.
